Literature DB >> 10620452

Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy.

T C Randall1, G Coukos, J E Wheeler, S C Rubin.   

Abstract

BACKGROUND: Placental site trophoblastic tumor (PSTT) is a form of gestational trophoblastic neoplasm that is frequently resistant to chemotherapy. In most cases disease is confined to the uterus and can be cured by curettage or simple hysterectomy. Patients with metastases, however, frequently have progression of disease and die despite aggressive multiagent chemotherapy. CASE: A 31-year-old woman was found on review of uterine curettings to have a PSTT. Imaging studies revealed multiple lung lesions, a liver lesion, and an enlarged irregular uterus. Hysterectomy and staging surgery revealed a large tumor in the endometrial cavity and multiple metastases. She was treated with etoposide-methotrexate-dactinomycin and cyclophosphamide-vincristine and had a complete clinical remission. Six months later, however, she had a recurrence. She was then treated with six cycles of etoposide-methotrexate-dactinomycin and etoposide-cisplatin. Three years after completion of the second regimen she is without evidence of disease.
CONCLUSION: Treatment with multiagent chemotherapy can produce long-term remission, even in patients with recurrent, metastatic PSTT. Addition of platinum may be helpful in patients who have recurred or progressed after treatment with non-platinum-containing regimens. Copyright 2000 Academic Press.

Entities:  

Mesh:

Year:  2000        PMID: 10620452     DOI: 10.1006/gyno.1999.5654

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

Review 1.  Placental site trophoblastic tumor.

Authors:  Nadereh Behtash; Mojgan Karimi Zarchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-16       Impact factor: 4.553

2.  Placental-site trophoblastic tumor with PET scan-detected surgically treated lung metastasis.

Authors:  Lucybeth Nieves; James Hoffman; Gretchen Allen; John Currie; Joel I Sorosky
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.